Format

Send to

Choose Destination
Front Oncol. 2012 Nov 28;2:173. doi: 10.3389/fonc.2012.00173. eCollection 2012.

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Author information

1
Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University Newcastle, UK.

Abstract

Neuroblastoma is the most common extra-cranial solid tumor of childhood. Despite significant advances, it currently still remains one of the most difficult childhood cancers to cure, with less than 40% of patients with high-risk disease being long-term survivors. MYCN is a proto-oncogene implicated to be directly involved in neuroblastoma development. Amplification of MYCN is associated with rapid tumor progression and poor prognosis. Novel therapeutic strategies which can improve the survival rates whilst reducing the toxicity in these patients are therefore required. Here we discuss genes regulated by MYCN in neuroblastoma, with particular reference to p53, SKP2, and DKK3 and strategies that may be employed to target them.

KEYWORDS:

DKK3; MDM2-p53 antagonists; MYCN; SKP2; neuroblastoma; p53

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center